Survival among patients with composite and sequential lymphoma between primary mediastinal lymphoma/diffuse large B-cell lymphoma and classical Hodgkin lymphoma: A population-based study

Leuk Res. 2021 Dec:111:106669. doi: 10.1016/j.leukres.2021.106669. Epub 2021 Jul 16.

Abstract

Background: Data on composite and sequential lymphoma between primary mediastinal lymphoma/diffuse large B-cell lymphoma (LBCL) and classical Hodgkin lymphoma (cHL) are rare.

Methods: We identified 25 cases with composite lymphoma (CL), 116 cases developing LBCL as a second primary cancer after cHL (cHL-LBCL), and 74 cases developing cHL as a second primary cancer after LBCL (LBCL-cHL) from the Surveillance, Epidemiology, and End Results (SEER) 18 database. Comparisons of overall survival (OS) and lymphoma cause-specific survival (CSS) between patients with cHL-LBCL or cHL-LBCL and their de novo counterparts were performed.

Results: The 5-year OS of patients with CL was 74.8 %. No significant difference in unadjusted OS and lymphoma CSS were observed between patients with de novo LBCL (LBCL-1 group) and patients with cHL-LBCL. However, the age- and stage-adjusted cHL-LBCL group had inferior OS and lymphoma CSS compared with that in the LBCL-1 group. The unadjusted and adjusted OS and lymphoma CSS in the LBCL-cHL group were significantly worse than patients with de novo cHL.

Conclusions: CL between LBCL and cHL may have good outcomes. cHL survivors had poorer outcomes after a LBCL diagnosis versus patients with LBCL-1. Significantly poor outcomes were observed in patients with LBCL-cHL compared with patients with de novo cHL.

Keywords: Classical Hodgkin lymphoma; Composite lymphoma; Population-based study; Primary mediastinal lymphoma/diffuse large B-cell lymphoma; Sequential lymphoma.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Chemoradiotherapy / mortality*
  • China / epidemiology
  • Female
  • Follow-Up Studies
  • Hodgkin Disease / epidemiology
  • Hodgkin Disease / mortality*
  • Hodgkin Disease / pathology
  • Hodgkin Disease / therapy
  • Humans
  • Lymphoma, Large B-Cell, Diffuse / epidemiology
  • Lymphoma, Large B-Cell, Diffuse / mortality*
  • Lymphoma, Large B-Cell, Diffuse / pathology
  • Lymphoma, Large B-Cell, Diffuse / therapy
  • Male
  • Mediastinal Neoplasms / epidemiology
  • Mediastinal Neoplasms / mortality*
  • Mediastinal Neoplasms / pathology
  • Mediastinal Neoplasms / therapy
  • Middle Aged
  • Neoplasms, Second Primary / epidemiology
  • Neoplasms, Second Primary / mortality*
  • Neoplasms, Second Primary / pathology
  • Neoplasms, Second Primary / therapy
  • Prognosis
  • Retrospective Studies
  • Survival Rate
  • Young Adult